

February 10, 2023

The Manager – Listing
BSE Limited
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s)

Sub: Outcome of the Board Meeting held on Friday, February 10, 2023 pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

In continuation of our letter dated January 30, 2023, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e., Friday, February 10, 2023 *inter alia* considered and approved the Unaudited Financial Results for the quarter ended December 31, 2022 based on the recommendation of the Audit Committee. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors dated February 10, 2023 are enclosed herewith.

The Meeting commenced at 2:30 P.M. and concluded at 5.00 P.M. (IST).

Kindly take the above information on your records.

Thanking you
Yours faithfully

For AstraZeneca Pharma India Limited


Rajesh Marwaha
Chief Financial Officer and Director
DIN: 01458768



Encl: As above

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bengaluru 560 045
 Statement of unaudited financial results for the quarter and nine months ended 31 December 2022

Sl No.	Particulars	Rs in lakhs except for earnings per share data					
		3 months ended 31/12/2022	Previous 3 months ended 30/09/2022	Corresponding 3 months ended in the previous year 31/12/2021	9 months ended 31/12/2022	9 months ended 31/12/2021	Year ended 31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	a) Revenue from operations	24,880.85	23,612.68	26,052.72	71,626.73	67,393.68	80,560.01
	b) Other income	719.61	679.43	533.06	1,810.46	1,107.37	1,475.76
	Total income	25,700.46	24,292.11	26,586.78	73,437.19	68,501.05	82,035.77
2	Expenses						
	(a) Cost of materials consumed	2,710.45	1,976.28	2,957.74	6,275.88	3,689.07	3,961.08
	(b) Purchase of stock-in-trade	7,424.49	7,118.48	3,061.97	22,074.42	14,809.51	20,789.07
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(868.24)	(444.97)	1,248.89	(2,215.81)	1,139.70	1,447.01
	(d) Employee benefit expense	6,288.42	6,118.74	5,806.28	19,224.28	17,174.31	23,020.82
	(e) Depreciation expense	415.23	328.70	350.55	1,201.11	1,284.23	1,694.89
	(f) Allowance for expected credit loss (net)	46.00	(19.25)	65.69	125.74	295.18	399.93
	(g) Selling, marketing and distribution expense	2,078.71	1,443.24	1,445.73	4,895.45	3,457.89	5,071.91
	(h) Other expenses	3,782.11	3,347.72	3,382.86	11,219.14	9,176.51	12,263.94
	(i) Finance costs	19.65	16.25	22.73	54.52	74.01	94.72
	Total expenses	21,764.82	19,885.17	18,859.32	62,554.71	63,870.48	73,732.15
3	Profit before tax (1-2)	3,845.64	4,406.94	1,828.46	11,082.48	4,630.57	8,303.62
4	Tax expense						
	- Current tax	984.57	1,239.89	447.64	2,992.07	1,341.51	2,282.94
	- Deferred tax charge/ (credit)	30.83	(89.48)	36.80	(111.72)	(101.89)	(116.80)
	Total tax expense	1,015.20	1,150.61	484.54	2,880.35	1,239.62	2,144.34
5	Profit after tax (3-4)	2,930.44	3,256.45	1,141.92	8,202.13	3,390.95	6,159.28
6	Other comprehensive income/(loss)						
	A. Items that will not be reclassified to profit or loss						
	Re-measurement gains/(losses) on post employment benefit obligations	(30.31)	(24.85)	(55.88)	(70.61)	(114.50)	(231.59)
	Income tax effect on above	9.14	6.25	14.07	17.77	28.82	58.29
	Total other comprehensive income/(loss), net of income tax	(27.17)	(18.60)	(41.81)	(52.84)	(85.68)	(173.30)
	Total comprehensive income for the period (5+6)	2,903.27	3,237.83	1,100.11	8,149.29	3,275.27	5,985.98
7	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00	500.00	500.00
8	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-	-	-	50,639.28
9	Earnings per equity share of Rs 2/- each (basic and diluted)	11.72	13.03	4.57	32.81	13.44	24.64

[Handwritten signature]




AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045

Statement of unaudited financial results for the quarter and nine months ended 31 December 2022

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 3 During January 2023, the Company has offered a voluntary separation scheme to certain employees. Management is in the process of determining the amount of settlement which would depend on the final acceptance by the employees. Accordingly, the expenses relating to the scheme will be recognised during the quarter ending 31 March 2023.
- 4 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 5 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 February 2023. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2022.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 10 February, 2023



AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited financial results for the quarter and nine months ended 31 December 2022

Sl No.	Particulars	Rs in lakhs except for earnings per share data		
		3 months ended 31/12/2022	Year to date figure for current period ended 31/12/2022	Corresponding 3 months ended in the previous year 31/12/2021
		Unaudited	Unaudited	Unaudited
1	Total income from operations	25,700.46	73,637.19	20,585.78
2	Net profit/(loss) for the period from ordinary activities before tax	3,945.64	11,082.48	1,626.46
3	Net profit/(loss) for the period from ordinary activities after tax	2,930.44	8,202.13	1,141.92
4	Total comprehensive income for the period after tax	2,903.27	8,149.29	1,100.11
5	Equity Share Capital	500.00	500.00	500.00
6	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-
7	Basic and diluted earnings per share (of Rs 2 each)	11.72	32.81	4.57

Note:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites (www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).
- The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Place: Bengaluru
Date: 10 February, 2023


Sanjeev Kumar Panchal
Managing Director

Price Waterhouse & Co Chartered Accountants LLP

Independent Auditors' Review Report on the Statement of Unaudited Financial Results

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park
Rachenahalli Outer Ring Road,
Bengaluru – 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended December 31, 2022 and the year to date results for the period April 1, 2022 to December 31, 2022, which are included in the accompanying 'Statement of unaudited financial results for the quarter and nine months ended 31 December 2022' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009

PADAR MAHABALA
BHAT PRASANNA

Digitally signed by PADAR
MAHABALA BHAT PRASANNA
Date: 2023.02.10 17:07:24 +05'30'

Prasanna Padar Mahabala
Partner
Membership Number: 206477
UDIN: 23206477BGXCJK6126

Place: Dubai
Date: February 10, 2023

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor
Bengaluru - 560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)